Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity” or "the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Stockhead on MSN
Alterity delivers encouraging phase II data in MSA trial
Alterity has presented promising phase II trial data of lead compound ATH434 in multiple system atrophy at an international ...
Emory researchers reveal a strong link between mental health and heart disease, showing some disorders can raise heart risks by up to 100%.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈